Vital Diagnostics Inc has signed an exclusive agreement with Cardinal Health, Dublin Ohio, to sell the PATHFAST point-of-care chemiluminescence immunoassay analyzer in the US. Cardinal will have exclusive rights to sell the PATHFAST into hospital emergency rooms, coronary care units, and laboratories, including satellite laboratories.
The PATHFAST system is a unique, self-contained, bench-top chemiluminescence immunoassay analyzer that rapidly measures concentrations of emergency biomarkers from a single whole blood sample. Manufactured and sold worldwide by Mitsubishi Chemical Medience Corp, the PATHFAST offers a complete cardiovascular menu, which includes Cardiac Troponin I (cTnI), N-terminal pro brain natriuretic peptide (NT-proBNP), D-Dimer, Myoglobin, Creatinine Kinase (CK-MB), and high-sensitivity Creactive protein (hsCRP). The system directly utilizes a whole blood sample, eliminating the need for centrifugation of the specimen. With a 17-minute turnaround time, critical results are available to the physician quickly, enhancing patient care.
Source: Vital Diagnostics
